8-K: Castle Biosciences Reports Strong Q1 2025 Results, Raises Full-Year Revenue Guidance

Castle Biosciences announces a 21% increase in Q1 2025 revenue, driven by core test growth, and raises its full-year 2025 revenue guidance.

Summary

• Castle Biosciences reported its financial results for the first quarter ended March 31, 2025.
• Q1 2025 revenues increased by 21% to $88.0 million, compared to $73.0 million in Q1 2024.
• Adjusted revenues were $87.2 million, a 22% increase from $71.3 million in the same period last year.
• The company delivered 24,402 total test reports in Q1 2025, a 17% increase compared to 20,888 in Q1 2024.
• DecisionDx-Melanoma test reports were 8,621, DecisionDx-SCC test reports were 4,375, and TissueCypher Barretts Esophagus test reports were 7,432.
• The company discontinued the IDgenetix test offering, effective May 2025, resulting in an acceleration of amortization expense of approximately $20.1 million during the three months ended March 31, 2025.
• Net loss was $25.8 million, compared to a net loss of $2.5 million for the same period in 2024, which includes non-cash stock-based compensation expense of $11.2 million.
• Adjusted EBITDA was $13.0 million, compared to $10.5 million for the same period in 2024.
• As of March 31, 2025, cash, cash equivalents, and marketable investment securities totaled $275.2 million.
• Castle Biosciences is raising its full-year 2025 revenue guidance to $287-297 million, compared to the previous guidance of $280-295 million.
• The company also announced it signed a definitive agreement to acquire Previse, a gastrointestinal health company.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, increased test volume, and raised revenue guidance. While there is a net loss, it is attributed to a one-time amortization expense, and the company maintains a strong cash position. The acquisition of Previse further contributes to a positive sentiment.

Positives

• Revenue increased by 21% in Q1 2025 compared to Q1 2024.
• Core revenue drivers saw a 33% increase in test reports.
• Full-year 2025 revenue guidance has been raised.
• DecisionDx-Melanoma has surpassed 200,000 test orders.
• Adjusted EBITDA increased compared to the same period last year.
• The company has a strong cash position.
• The acquisition of Previse expands the company's portfolio in gastroenterology.

Negatives

• Net loss increased significantly to $25.8 million, compared to $2.5 million in the same period last year, due to an acceleration of amortization expense related to the discontinued IDgenetix test.
• Gross margin was impacted by a one-time adjustment of an acceleration of amortization expense of approximately $20.1 million during the three months ended March 31, 2025.
• The company discontinued the IDgenetix test offering, effective May 2025.

Risks

• The company's assumptions regarding reimbursement for its products and subsequent coverage decisions could impact future revenue.
• Macroeconomic events and conditions, including inflation, labor shortages, and geopolitical events, could affect the business.
• Subsequent study or trial results may contradict earlier findings.
• The newer gastroenterology and mental health franchises may not contribute to the achievement of long-term financial targets as anticipated.

Future Outlook

Castle Biosciences anticipates generating between $287-297 million in total revenue in 2025 and aims to be net operating cash flow positive by the end of 2025.

Management Comments

• Derek Maetzold, president and chief executive officer of Castle Biosciences, stated that they are pleased with the exceptional start to the year, marked by continued growth in test report volume and revenue.
• Maetzold believes their ongoing success reflects the high clinical value of their tests and consistent execution and teamwork.
• Maetzold is especially pleased that DecisionDx-Melanoma recently achieved a significant milestone, surpassing 200,000 test orders since the launch of the test.
• Maetzold stated that the company's first-quarter results demonstrate their leadership across their proprietary, first-to-market test portfolio and unwavering commitment to impacting patient outcomes.

Industry Context

Castle Biosciences operates in the diagnostics industry, focusing on innovative tests that guide patient care in dermatology, gastroenterology, ophthalmology, and mental health. The company's growth is driven by the increasing demand for personalized medicine and the clinical utility of its tests in improving patient outcomes.

Comparison to Industry Standards

• Castle Biosciences competes with companies like Exact Sciences, Genomic Health (now part of Exact Sciences), and Myriad Genetics in the molecular diagnostics market.
• Castle's focus on proprietary, first-to-market tests and robust clinical evidence differentiates it from some competitors.
• The company's DecisionDx-Melanoma test is considered a standard of care in uveal melanoma, demonstrating its strong market position in that segment.
• The growth in TissueCypher test reports indicates increasing adoption in the gastroenterology space, competing with traditional diagnostic methods for Barrett's esophagus.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and raised guidance.
• Clinicians will have access to innovative tests that guide patient care.
• Patients will benefit from improved diagnostic and treatment options.
• Employees will be part of a company recognized as a top workplace.

Next Steps

• The company will hold a conference call on May 5, 2025, to discuss the first quarter 2025 results and provide a corporate update.
• Castle Biosciences expects to close the acquisition of Previse in the coming weeks.
• The company plans to continue driving growth initiatives and advancing its pipeline expansion.
• Assuming successful validation, expect launch of Atopic Dermatitis Gene Expression Profile Test by the end of 2025.

Key Dates

Keywords

Castle Biosciences, financial results, revenue, test reports, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, Previse, diagnostics, genomics